Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PELITREXOL/AG-2037 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PELITREXOL/AG-2037 | DRUG | - |
Inclusion Criteria: * Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum * Stage IV or recurrent disease * Measurable disease * Disease progression or recurrence during or after completion of prior first-line chemotherapy with fluorouracil and leucovorin calc...
PELITREXOL/AG-2037 is an investigational small molecule being studied for the treatment of colorectal neoplasms, specifically in patients with metastatic colorectal cancer who have failed prior treatment. It is currently in Phase 2 clinical development.
PELITREXOL/AG-2037 is a GARFT inhibitor, meaning it targets the enzyme glycinamide ribonucleotide formyltransferase, which is involved in the de novo purine biosynthesis pathway. By inhibiting GARFT, the drug aims to disrupt DNA synthesis in cancer cells.
PELITREXOL/AG-2037 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
PELITREXOL/AG-2037 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and no active trials are currently listed.
PELITREXOL/AG-2037 has been studied in one completed Phase 2 clinical trial, identified as NCT00078468. This trial enrolled 56 patients with metastatic colorectal cancer who had failed prior treatment and was conducted in the United States.
Yes, PELITREXOL/AG-2037 is also known as AG-2037. Both names refer to the same investigational drug being developed by Pfizer for the treatment of colorectal neoplasms.